On November 1, 2024, Christopher S. Boerner, the Chief Executive Officer of Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Boerner acquired 2,964 shares at no cost, typically indicative of the exercise of options or similar derivative securities. On the same day, he disposed of a total of 1,543 shares. The disposals included 55 shares at no reported price and 1,488 shares at a price of $54.32 per share, the latter likely related to the payment of exercise price or tax liability by delivering or withholding securities. Following these transactions, Boerner's direct holdings in Bristol-Myers Squibb amounted to 102,626 shares. The total market value of the disposed shares was calculated at $80,828.16.

On November 1, 2024, Christopher S. Boerner, the Chief Executive Officer of Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Boerner acquired 2,964 shares at no cost, typically indicative of the exercise of options or similar derivative securities. On the same day, he disposed of a total of 1,543 shares. The disposals included 55 shares at no reported price and 1,488 shares at a price of $54.32 per share, the latter likely related to the payment of exercise price or tax liability by delivering or withholding securities. Following these transactions, Boerner's direct holdings in Bristol-Myers Squibb amounted to 102,626 shares. The total market value of the disposed shares was calculated at $80,828.16.